Results 21 to 30 of about 54,010 (241)

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Stemmler, J., Hacker, U., Schalhorn, A., Weise, A., Heinemann, Volker   +4 more
core   +1 more source

A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

Clinical and Translational Science, 2022
Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both agents may exacerbate irinotecan toxicity.
Olumide B. Gbolahan, Bert H. O’Neil, Autumn J. McRee, Hanna K. Sanoff, John K. Fallon, Philip C. Smith, Anastasia Ivanova, Dominic T. Moore, Julie Dumond, Gary N. Asher   +9 more
doaj   +1 more source

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses [PDF]

, 2012
Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Hartley, J.A., MacPherson, I.R.J., Masanori Miwa, Hartley, JM, Jones, K, Crawford Donna, Saito Tomohisa, Evans, TRJ, Hartley, JA, Jones Keith, MacPherson, IRJ, Abe Masaichi, Crawford, D, Jones, K., D Alan Anthoney, John M Hartley, Saito, T., Twelves, C., Hartley Janet A, Anthoney, D.A., Christopher Twelves, Anthoney, DA, Miwa, M., Miwa Masanori, TRJ Evans, Evans, T.R.J., Naik, J, Jay Naik, Donna Crawford, Keith Jones, Abe, M., Saito, T, Tomohisa Saito, Abe, M, Naik Jay, Naik, J., MacPherson Iain RJ, Evans TRJ, Hartley, J.M., Hartley John M, Masaichi Abe, Miwa, M, Twelves, C, Crawford, D., Anthoney D, Janet A Hartley, Twelves Christopher, Iain RJ MacPherson   +47 more
core   +1 more source

Determination of Irinotecan enantiomer impurity in Irinotecan Hydrochloride API by using reverse-phase liquid chromatography

, 2023
To evaluate and quantify Irinotecan (R-enantiomer) / Irinotecan related compound D in Irinotecan hydrochloride trihydrate API, a high stereo-specific liquid chromatography technique was developed and validated.
Srinivas P, Vijay, Vijay Srinivas P, Manjusha K, Gana, Vinukonda, Anjaneyulu, Gana Manjusha K, Anjaneyulu Vinukonda   +5 more
core   +2 more sources

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

BMC Cancer, 2018
Background The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.
Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau, Céline Gongora   +12 more
doaj   +1 more source

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Oncology and Therapy, 2023
Introduction Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher for liposomal ...
Sandrine Barbier, Benjamin Beaufils, Ricardo de Miguel, Melissa Reyre, Yannick Le Meitour, Andreanne Lortie, Marc Hillairet de Boisferon, Sophie Chaumeron, Anne Espirito, Lina Fossati, Pauline Lagarde, Stephan Klinz, Arunthathi Thiagalingam, Stéphane Lezmi, Florence Meyer-Losic   +14 more
doaj   +1 more source

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications, 2019
Background The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational ...
Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang   +21 more
doaj   +1 more source

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity

Cancer Medicine, 2023
Objective Irinotecan is a useful anticancer drug for colorectal cancer treatment. UGT1A1*28 and *6 gene polymorphisms are known risk factors for irinotecan‐associated toxicity.
Kou Kanesada, Ryouichi Tsunedomi, Shoichi Hazama, Hiroyuki Ogihara, Yoshihiko Hamamoto, Yoshitaro Shindo, Hiroto Matsui, Yukio Tokumitsu, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tatsuya Ioka, Hiroaki Nagano   +13 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report

Clinical Medicine Insights: Case Reports, 2023
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms.
Yu-Ting Shun, Hsien-Yung Lai, Yi-Ting Chuang, Hsuen-Fu Lin   +3 more
doaj   +1 more source